Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Authors
Keywords
Myeloma, Drug resistance, Proteasome inhibitors, MDR1
Journal
LEUKEMIA RESEARCH
Volume 101, Issue -, Pages 106499
Publisher
Elsevier BV
Online
2021-01-01
DOI
10.1016/j.leukres.2020.106499
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The addition of a HIV protease inhibitor to carfilzomib therapy in myeloma overcomes ABCB1-mediated drug resistance: a proof of concept
- (2019) Rory Bennett et al. Clinical Lymphoma Myeloma & Leukemia
- Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
- (2018) Praful Ravi et al. Blood Cancer Journal
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- Melflufen - a peptidase-potentiated alkylating agent in clinical trials
- (2017) Malin Wickström et al. Oncotarget
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
- (2016) G P Soriano et al. LEUKEMIA
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
- (2015) A. Gulla et al. CLINICAL CANCER RESEARCH
- First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
- (2015) Åke Berglund et al. INVESTIGATIONAL NEW DRUGS
- KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models
- (2015) Irene Riz et al. Oncotarget
- Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
- (2013) Teresa S. Hawley et al. AMERICAN JOURNAL OF HEMATOLOGY
- Extramedullary multiple myeloma
- (2012) Matthew Weinstock et al. LEUKEMIA & LYMPHOMA
- Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
- (2012) Masanobu Tsubaki et al. LEUKEMIA RESEARCH
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now